Navigation Links
New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development

SCOTTSDALE, Ariz., July 8 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Rheumatoid Arthritis (RA) therapies.

In this report, entitled Thought Leader Insight & Analysis: Rheumatoid Arthritis Q2 2008, MedPredict's global Thought Leader Panel reviews progress in developing biological and small molecule regimens for the treatment of early RA.

According to this report, the key change in practice occurring in the treatment of RA is the push toward earlier diagnosis and treatment, which is associated with more durable remission. New biomarkers and approaches to cellular imaging in early disease are also being investigated.

"Our Panel sheds light on which companies are likely to be positioned to capitalize on this trend," says MedPredict President Jeffrey D. Berk. "In addition, they offer predictions on how tocilizumab, certolizumab and golimumab will compete with the established biologicals, and how the current market leaders are positioning to defend their brands in the RA space. Their discussion will provide essential strategic and competitive insight for anyone with a stake in this market."

The report also addresses pain management in RA, provides a postmortem on the rituximab non-renal lupus trial, and discusses the most meaningful clinical developments related to the following mechanisms: Anti-TNF, Anti-CTLA, Anti-IL-1, Anti-IL-6, Antiresorptives, Anti-IL-17, p38 MAP kinase, JAK, Syk, PDE5, and more.

Companies mentioned in this report include: Abbott, Amgen, Amgen/Takeda Bio, Amgen/Wyeth, AstraZeneca/MedImmune, Biogen, Bristol-Myers Squibb, Celgene, Centocor, Centocor/Schering-Plough/Essex, GlaxoSmithKline/Genmab, Human Genome Sciences, Incyte, Merck Serono/ZymoGenetics, Novartis, Oxypharma, Pfizer, Roche/Chugai, Roche/Genentech, Sanofi-Aventis/Regeneron, UCB, Vertex and Wyeth/Trubion.

MedPredict conducted in-depth, primary interviews with leading rheumatologists from North America and Europe to provide the basis for this report.

This report can be purchased by contacting MedPredict.

About MedPredict

MedPredict ( maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.

SOURCE MedPredict Market Research
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. In Pain Market, Huge Unmet Needs, Tough Regulatory Environment Challenge Pharmaceutical Companies, According to MedPredict
2. Thought Leaders Discuss Positive Outlook for Bapineuzumab in Alzheimers Disease in MedPredict Report
3. New MedPredict Report Suggests Market for Alcoholism Therapies is Underestimated
4. Unmet Needs Provide Challenges and Opportunities for Rheumatoid Arthritis Drug Developers According to MedPredict Report
5. Pipeline for Lung Cancer Therapies is Focus of New MedPredict Report
6. Knowledge Enterprises, Inc. and The Institute for Orthopaedics(TM) Release The 2007-2008 Orthopaedic Industry Annual Report
7. Galaxy Nutritional Foods Reports FY2008 Results
8. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
9. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
10. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
11. Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  The Minnesota High Tech Association ... 2015 Tekne Award in the Small and Growing Healthcare ... Minneapolis Convention Center, the Tekne ... significant role in developing new technologies that positively impact ... world. Clostridium difficile infection ( C. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... specializing in scientifically backed, age-defying products, is featured as the cover story ... exponential success and unrivaled opportunities that Nerium provides. Success from Home magazine ...
(Date:12/1/2015)... ... December 01, 2015 , ... Matthew “Tex” VerMilyea, PhD, HCLD, has ... will oversee all IVF lab procedures as well as continue his research efforts ... traveled 7,305 miles to Auckland, New Zealand to bring home a High Complexity Clinical ...
(Date:11/30/2015)... ... ... Global Stem Cells Group announced the opening of a new core patient care ... in northern Chile. The facilities are part of GSCG’s expansion efforts in Latin America. ... stem cell medicine to patients from around the world. , The clinics will be headed ...
Breaking Biology Technology:
(Date:11/9/2015)... Nov. 09, 2015 ... of the "Global Law Enforcement Biometrics ... --> ) has announced ... Enforcement Biometrics Market 2015-2019" report to ... Markets ( ) has announced the ...
(Date:10/29/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that it has ... as one of only three finalists for a ... and Growing" category. The Tekne Awards honor Minnesota ... technology innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... the explosion of technology-enabled health and wellness, and the ... book, The Internet of Healthy Things ... or smartphones even existed, Dr. Kvedar, vice president, Connected ... health care delivery, moving care from the hospital or ...
Breaking Biology News(10 mins):